Core Viewpoint - BGM Group is set to release its unaudited financial results for the first half of 2025 on July 24, 2025, before U.S. financial markets open [1] Company Overview - BGM Group Ltd. focuses on technology sectors including AI applications, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [2] AI Application Implementation - The company utilizes advanced analytics and AI Agent technology through its platforms Du Xiao Bao and Bao Wang to deliver AI solutions and intelligent robot services to insurance companies, brokers, and consumers [3] - Services encompass sales and marketing, underwriting assessment, claims processing, and customer service, with capabilities in consumer data analysis and customized service provision [3] Biopharmaceuticals Division - BGM's biopharmaceutical division produces oxytetracycline API, crude heparin sodium, and licorice preparations, serving global markets in animal husbandry, pharmaceuticals, and drug retail [4] - The integration of AI-assisted decision-making enhances production efficiency, supply chain optimization, and market trend prediction, providing a scientific basis for management decisions and high-quality products for consumers [4]

Group 1 - BGM Group Ltd. has completed the acquisition of YX Management Company Ltd., enhancing its capabilities in intelligent mobility technology, with a valuation of US$95.0 million [1][2] - Following the acquisition, YX's shareholders own approximately 32.6% of BGM's equity interests and about 2.2% of the total voting power [1] - The acquisition is a significant step in BGM's AI-driven transformation, aimed at integrating AI into its core businesses, including intelligent insurance and digital services [2][3] Group 2 - The CEO of BGM stated that the integration of YX's expertise will accelerate the application of AI across key sectors, advancing towards an AI Agent-driven model [3] - BGM focuses on technology fields such as AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [4] - The group utilizes advanced analytics and AI Agent technology to provide comprehensive AI solutions for insurance companies, covering various key scenarios [5] Group 3 - In the biopharmaceutical sector, BGM's division produces oxytetracycline API, crude heparin sodium, and licorice preparations, integrating AI-assisted decision-making for supply chain optimization [6]

Core Viewpoint - BGM Group Ltd. has signed a definitive agreement to acquire 100% of YX Management Company Ltd. for US$95 million, which will enhance BGM's AI-driven platform, DuXiaoBao, and is expected to be completed by June 2025 [1][3]. Group 1: Acquisition Details - BGM will issue 47.5 million class A ordinary shares to acquire YX, valuing the company at US$95 million [1]. - Following the acquisition, YX's shareholders will hold approximately 32.8% of BGM's total outstanding shares and about 2.2% of its voting power [1]. Group 2: YX Team Expertise - The YX team consists of executives and technology experts from major Chinese internet companies like Alibaba and Didi, with experience in large-scale platform development [2]. - Core members have been involved in significant projects such as Taobao Mobile and Didi's ride-hailing services, showcasing their capabilities in digital transformation and AI commercialization [2]. Group 3: Strategic Impact - The integration of the YX team is expected to create a "multiplier effect" through industry breakthroughs and ecosystem synergy, enhancing BGM's leadership in intelligent technology innovation [3]. - The operational experience and strategies of the YX team will position AI as a key driver for BGM's value growth and sustainable returns [3]. Group 4: Company Focus Areas - BGM Group Ltd. focuses on AI applications, intelligent robots, algorithmic computing, cloud computing, and biopharmaceuticals [4]. - The company utilizes big data and AI technologies to provide solutions for insurance companies, covering various scenarios like sales, underwriting, and customer service [5]. - In biopharmaceuticals, BGM produces key products for global markets, integrating AI for supply chain optimization and process efficiency [6].